Drugs / vicasinabin
vicasinabin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04265261 | Jun 2020 → Jul 2023 | diabetic retinopathy | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vicasinabin | “The objective of CANBERRA was to assess the safety, tolerability, and efficacy of oral administration of vicasinabin (RG7774) on the severity of diabetic retinopathy (DR) in...” PMID 39802207 ↗ Nov 2024 |
| Known as | RG7774 | “The objective of CANBERRA was to assess the safety, tolerability, and efficacy of oral administration of vicasinabin (RG7774) on the severity of diabetic retinopathy (DR) in...” PMID 39802207 ↗ Nov 2024 |
| Known as | RO-6868847 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314566 ↗ |
| Modality | Small molecule | — CHEMBL5314566 ↗ |
| Route | Oral | “oral administration of vicasinabin (RG7774)” PMID 39802207 ↗ Nov 2024 |